

### **REMARKS/ARGUMENTS**

Responsive to the Restriction Requirement mailed December 21, 2005, Applicant elects Group 6, claims 19-21, drawn to the method.

In response to the further requirement for election, Applicant's specific composition is elected to include a S/MP as a conjugate of testosterone and serum albumin or testosterone conjugated to BSA and the CAD as Taxol or Taxotere. This would include usual pharmaceutical excipients, diluents, etc., which are not specifically claimed, but are within a claim having a "comprising" transition.

It is noted that claim 19 is dependent upon claim 13. Applicant submits that claim 13 does describe a specific composition comprised of the constituents in claim 13 with the specific S/MP conjugate and CAD, as indicated hereinabove. It is now apparent that any further constituents of this composition have been accounted for in view of the wording of claim 19. The undersigned therefore asks that if further constituents of some sort are to be specified, that a request explaining what is needed be mailed.

As to the specific cancer, Applicant elects prostate cancer. Reconsideration of this specific cancer specifying is requested in view of the above election of the S/MP and CAD.

Non-elected claims 1-18 and 22-27 have been canceled, without prejudice to filing of divisional applications during the pendency of this application. This saves extra claim fees.

New claims 28-47 have been added.

Claims 28, 29 and 30, correspond in their claim elements to the elements of claims 19, 20 and 21, respectively. Although claims 28-30 are not identical to claims 19-21, respectively, the contents of claims 28-30 are such that they are linked to the same invention as the three elected claims and therefore claims 28-30 should be elected here as well. If, for any reason, it is believed that claims 19-21 are non-statutory or improper in the United States, Applicant would agree to substitution of claims 28-30 as the elected claims, since in Applicant's view, they cover the same invention in different form.

Because each of new claims 31-43 is dependent upon claim 28 and, it is submitted, because claim 28 is a claim in Group 6, claims 31-43 should also be deemed as claims in the elected Group 6 and should be examined with claims 19-21. Alternatively, it may be said that claims 31-43 provide a specific composition in which all constituents are accounted for, as requested in the further election after Group 6 is elected.


It is further submitted that claims 44-47 should be deemed elected claims, as they concern the same subject as and are method claims like claims 19-21 and 28-30.

New claims 31-47 find support in the specification and drawings as originally filed. In particular, support for the new claims is found at the indicated pages of the specification: claim 33, page 6; claim 34, page 7; claim 35, page 7; claim 36, page 7; claim 37, page 12; claim 38, page 10; claim 39, pages 9, 10; claim 40, page 8; claim 41, page 9; claim 42, page 10; claim 43, page 32 and Figures 8 and 9; claim 44, pages 6, 7 and 19; claim 45, page 10; claim 46, no reference stated here; and claim 47, page 32 and Figures 8 and 9.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 21, 2006:

Robert C. Faber

Name of applicant, assignee or  
Registered Representative



Signature

March 21, 2006

Date of Signature

RCF:mjb

Respectfully submitted,



Robert C. Faber

Registration No.: 24,322

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700